<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360683</url>
  </required_header>
  <id_info>
    <org_study_id>2011_41</org_study_id>
    <secondary_id>2013-A00193-42</secondary_id>
    <nct_id>NCT02360683</nct_id>
  </id_info>
  <brief_title>Predictive Factors and Subthalamic Stimulation in Parkinson's Disease</brief_title>
  <acronym>PREDI-STIM</acronym>
  <official_title>Predictive Factors for Therapeutic Response of Subthalamic Stimulation on Quality of Live in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study identify preoperative predictors of response to subthalamic stimulation at 1 year,
      3 years and 5 years in terms of quality of life, from a broad prospective multicenter study
      French with standardized collection of clinical data , imaging and genetic .

      The investigators want to identify factors that predict the improvement of quality of life
      for one year corresponding to a decrease of PDQ39 score of at least 20 %. They believe that
      improvement would be less likely to become zero to 3 or 5 years and question the indication
      of the subthalamic stimulation (risks and costs). This is part of a process of
      &quot;personalization&quot; of the therapeutic care that is of any interest to the subthalamic
      stimulation. It is a therapeutic option that could be dangerous if patient selection is not
      optimal , and expensive, if the benefit is not large enough to reduce the number of
      medications and hospitalizations medium term . In addition, it will quantify the improvement
      of quality of life in the longer term and harmonize national assessments .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2013</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improve of quality of life on PDQ39&gt;20%</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of motor score MDS-UPDRS III improve under stimulation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socio-familial evolution (institutionalization)</measure>
    <time_frame>1, 3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Patient by 7-point scale</measure>
    <time_frame>1, 3 and 5 years</time_frame>
    <description>with the CGI-scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of doctor by 7-point scale</measure>
    <time_frame>1, 3 and 5 years</time_frame>
    <description>with the CGI-scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1, 3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function with a neuropsychological examination</measure>
    <time_frame>1, 3 and 5 years</time_frame>
    <description>with Mattis scale, Wisconsin Card Sorting test, Stroop test, , verbal episodic memory test with 16 items, phonemic and semantic verbal fluency, Boston naming test (15 items), clock drawing and Benton line orientation task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior test</measure>
    <time_frame>1, 3 and 5 years</time_frame>
    <description>ECMP scale of Ardouin 2009, Hamilton depression scale, Anxiety Hamilton scale, Lille Apathy Rating Scale, QUIP questionnaire, Billieux Impulsivity Scale, Hallucination questionnaire of Miami</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor response rates to Levodopa</measure>
    <time_frame>1, 3 and 5 years</time_frame>
    <description>with the difference of the motor handicap measured by MDS UPDRS part III before and after an acute L-dopa challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-motor functions evaluated by a numerical evaluation scale</measure>
    <time_frame>screening and at 1, 3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>patients with Parkinson's disease</arm_group_label>
    <description>Large population of Parkinson's patients who benefit from subthalamic stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patients with Parkinson's disease</intervention_name>
    <arm_group_label>patients with Parkinson's disease</arm_group_label>
    <other_name>systematic and standardized collection of data</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Multicentric French cohort of 1000 Parkinson's disease patients, for obtain 400 patients in
        the failure group
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving a pre- therapeutic assessment and therapeutic monitoring for one
             year , 3 years and 5 years as part of the regular monitoring of the subthalamic
             stimulation

          -  Bilateral STN stimulation considered

          -  Patient able to provide their free and informed consent

          -  Patient with insurance coverage

        Exclusion Criteria:

          -  Atypical Parkinson's disease do not meet the criteria of stuff .

          -  MP under 5 years

          -  Severe cognitive impairment or dementia ( Score Moca &lt;24 and DSM-IV criteria)

          -  Parkinson's Psychosis

          -  Reply to L- dopa &lt;30 %

          -  Against indication for surgery

          -  Severe brain atrophy or abnormal MRI

          -  The presence of another very serious condition terminal life- short-term prognosis (
             malignancy ) is an indication against .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David DEVOS, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David DEVOS, MD,PhD</last_name>
    <phone>+33320446752</phone>
    <phone_ext>+33</phone_ext>
    <email>david.devos@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Hôpital NORD</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Krystkowiak, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphane Thobois, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Gabriel-Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Franck Durif, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Devos</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Devos, MD, PhD</last_name>
      <phone>+33320446752</phone>
      <email>david.devos@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Francine Niset</last_name>
      <phone>+33320446752</phone>
      <email>francine.niset@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>caroline Moreau, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexandre Eusebio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Central,</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lucies Hopes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU hôpital Nord Laennec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tiphaine Rouaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caroline Giordana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cécile HUBSCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie Laure Marie Laure Welter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Luc Houeto, MD,Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie Drapier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Ch.Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Maltete, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Tranchant, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Rascol, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subthalamic neurostimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

